Belsomra and Zykadia

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of suvorexant, which is primarily metabolized by the isoenzyme. According to the product labeling, suvorexant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 1.3- and 2.8-fold, respectively, when coadministered with the potent CYP450 3A4 inhibitor ketoconazole (400 mg). MANAGEMENT: Concomitant use of suvorexant with potent CYP450 3A4 inhibitors should generally be avoided. References Cerner Multum, Inc. "Australian Product Information." O 0 "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of suvorexant, which is primarily metabolized by the isoenzyme. According to the product labeling, suvorexant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 1.3- and 2.8-fold, respectively, when coadministered with the potent CYP450 3A4 inhibitor ketoconazole (400 mg).

MANAGEMENT: Concomitant use of suvorexant with potent CYP450 3A4 inhibitors should generally be avoided.

Belsomra

Generic Name: suvorexant

Brand name: Belsomra

Synonyms: n.a.

What is Belsomra?

Zykadia

Generic Name: ceritinib

Brand name: Zykadia

Synonyms: n.a.

What is Zykadia?